These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 34403682)
21. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders. Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers. Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959 [TBL] [Abstract][Full Text] [Related]
23. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065 [TBL] [Abstract][Full Text] [Related]
24. SHP2: The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis. Chang CJ; Lin CF; Chen BC; Lin PY; Chen CL IUBMB Life; 2022 Feb; 74(2):131-142. PubMed ID: 34590785 [TBL] [Abstract][Full Text] [Related]
25. Strategies to overcome drug resistance using SHP2 inhibitors. Liu M; Gao S; Elhassan RM; Hou X; Fang H Acta Pharm Sin B; 2021 Dec; 11(12):3908-3924. PubMed ID: 35024315 [TBL] [Abstract][Full Text] [Related]
26. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET. Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847 [TBL] [Abstract][Full Text] [Related]
27. Targeted Degradation of the Oncogenic Phosphatase SHP2. Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482 [TBL] [Abstract][Full Text] [Related]
28. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules. Guo Z; Duan Y; Sun K; Zheng T; Liu J; Xu S; Xu J Eur J Med Chem; 2024 Sep; 275():116579. PubMed ID: 38889611 [TBL] [Abstract][Full Text] [Related]
29. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009 [TBL] [Abstract][Full Text] [Related]
30. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Agazie YM; Movilla N; Ischenko I; Hayman MJ Oncogene; 2003 Oct; 22(44):6909-18. PubMed ID: 14534538 [TBL] [Abstract][Full Text] [Related]
31. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors. Song Y; Zhao M; Wu Y; Yu B; Liu HM Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680 [TBL] [Abstract][Full Text] [Related]
32. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling. Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865 [TBL] [Abstract][Full Text] [Related]
33. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2. Matsuo K; Delibegovic M; Matsuo I; Nagata N; Liu S; Bettaieb A; Xi Y; Araki K; Yang W; Kahn BB; Neel BG; Haj FG J Biol Chem; 2010 Dec; 285(51):39750-8. PubMed ID: 20841350 [TBL] [Abstract][Full Text] [Related]
34. A novel partially open state of SHP2 points to a "multiple gear" regulation mechanism. Tao Y; Xie J; Zhong Q; Wang Y; Zhang S; Luo F; Wen F; Xie J; Zhao J; Sun X; Long H; Ma J; Zhang Q; Long J; Fang X; Lu Y; Li D; Li M; Zhu J; Sun B; Li G; Diao J; Liu C J Biol Chem; 2021; 296():100538. PubMed ID: 33722610 [TBL] [Abstract][Full Text] [Related]
35. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer. Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108 [TBL] [Abstract][Full Text] [Related]
36. A patent review of SHP2 allosteric inhibitors (2018-present). Petrocchi A; Ciammaichella A Expert Opin Ther Pat; 2024 May; 34(5):383-396. PubMed ID: 38842843 [TBL] [Abstract][Full Text] [Related]
37. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein. Wang M; Lu J; Wang M; Yang CY; Wang S J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146 [TBL] [Abstract][Full Text] [Related]
38. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. Zhang SQ; Tsiaras WG; Araki T; Wen G; Minichiello L; Klein R; Neel BG Mol Cell Biol; 2002 Jun; 22(12):4062-72. PubMed ID: 12024020 [TBL] [Abstract][Full Text] [Related]
39. Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers. Miao Y; Bai Y; Miao J; Murray AA; Lin J; Dong J; Qu Z; Zhang RY; Nguyen QD; Wang S; Yu J; Nguele Meke F; Zhang ZY J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38842946 [TBL] [Abstract][Full Text] [Related]
40. Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2. Zhang RY; Yu ZH; Chen L; Walls CD; Zhang S; Wu L; Zhang ZY J Biol Chem; 2020 May; 295(18):6187-6201. PubMed ID: 32188694 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]